Amgen said the FDA has given the breakthrough therapy designation to the company's new drug for adults with a rapidly progressing cancer of the blood and bone marrow.
via WSJ.com: US Business http://ift.tt/1mF3uzm
via WSJ.com: US Business http://ift.tt/1mF3uzm
Nessun commento:
Posta un commento